Timolol
- 1 January 1975
- journal article
- clinical trial
- Published by Springer Nature in Drugs
- Vol. 9 (3), 164-177
- https://doi.org/10.2165/00003495-197509030-00002
Abstract
Timolol (MK 950) is a new beta-adrenergic receptor blocking drug. It has little or no membrane stabilising ('quinidine-like') or partial agonist (intrinsic sympathomimetic) activity and thus resembles sotalol. On a weight for.weight basis, timolol is more potent than sotalol or propranolol. A 2.5 mg dose of timolol causes about the same reduction in resting heart rate as 20mg of propranolol. Results of placebo-controlled and of comparative trials with other beta-adrenergic receptor blocking drugs, have shown that timolol effectively lowers blood pressure without producing orthostatic or exercise hypotension. Findings of an international multicentre trial in angina pectoris, indicate that timolol is effective in reducing the frequency of anginal attacks and the consumption of glyceryl trinitrate for their relief.Keywords
This publication has 4 references indexed in Scilit:
- Potentiation of the Antihypertensive Action of Hydralazine by Timolol in Spontaneously Hypertensive RatsExperimental Biology and Medicine, 1974
- Some cardiovascular effects of timolol a new beta-adrenergic blocking agent.1973
- Antihypertensive and Hemodynamic Properties of the New Beta Adrenergic Blocking Agent TimololCirculation, 1973
- Comparison of a new beta adrenergic blocker (MK 950) and propranolol in manClinical Pharmacology & Therapeutics, 1972